BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 24057925)

  • 21. No evidence of splenic disease in patients with splenic marginal zone lymphoma undergoing splenectomy for autoimmune hemolytic anemia after monotherapy with rituximab.
    Kalpadakis C; Pangalis GA; Sachanas S; Rontogianni D; Korkolopoulou P; Milionis V; Vassilakopoulos TP; Papadaki HA; Angelopoulou MK
    Leuk Lymphoma; 2016 Nov; 57(11):2705-8. PubMed ID: 27082039
    [No Abstract]   [Full Text] [Related]  

  • 22. Risk-tailored treatment of splenic marginal zone lymphoma.
    Castelli R; Balzarotti M; Salvi E; Simona Rossi R; Lambertenghi Deliliers G; Bergamaschini L; Gidaro A
    Anticancer Drugs; 2022 Jan; 33(1):e36-e42. PubMed ID: 34407041
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Splenic marginal zone lymphoma: disease features and management.
    Matutes E
    Expert Rev Hematol; 2013 Dec; 6(6):735-45. PubMed ID: 24168526
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of splenic marginal zone lymphoma: should splenectomy be abandoned?
    Kalpadakis C; Pangalis GA; Vassilakopoulos TP; Sachanas S; Angelopoulou MK
    Leuk Lymphoma; 2014 Jul; 55(7):1463-70. PubMed ID: 24050506
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Multi-Database Description of Primary Splenic Diffuse Large B-Cell Lymphoma.
    Byrd KP; Vontela NR; McCullar B; Martin MG
    Anticancer Res; 2017 Dec; 37(12):6839-6843. PubMed ID: 29187463
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Aggressive variant of splenic marginal zone lymphoma characterized using a cancer panel test and treated with rituximab-containing chemotherapy: A case report.
    Ishiguro K; Sasaki Y; Takagi Y; Niinuma T; Suzuki H; Tokino T; Hayashi T; Takahashi T; Igarashi T; Matsuno Y
    Medicine (Baltimore); 2020 Aug; 99(35):e21938. PubMed ID: 32871937
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Splenic and nodal marginal zone lymphomas are indolent disorders at high hepatitis C virus seroprevalence with distinct presenting features but similar morphologic and phenotypic profiles.
    Arcaini L; Paulli M; Boveri E; Vallisa D; Bernuzzi P; Orlandi E; Incardona P; Brusamolino E; Passamonti F; Burcheri S; Schena C; Pascutto C; Cavanna L; Magrini U; Lazzarino M
    Cancer; 2004 Jan; 100(1):107-15. PubMed ID: 14692030
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Survival of patients with marginal zone lymphoma: analysis of the Surveillance, Epidemiology, and End Results database.
    Olszewski AJ; Castillo JJ
    Cancer; 2013 Feb; 119(3):629-38. PubMed ID: 22893605
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Progress on Treatment of Splenic Marginal Zone Lymphoma-Review].
    Wu L; Tian C; Zhang YZ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Apr; 25(2):600-603. PubMed ID: 28446319
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Clinicopathologic study of splenic marginal zone B-cell lymphoma].
    Zhang YN; Zheng YY; Zhou XG; Zhang SH; Jin Y; Xie JL; Chen SY; Shi Y; Wu LH
    Zhonghua Bing Li Xue Za Zhi; 2009 Apr; 38(4):243-7. PubMed ID: 19575895
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Significant efficacy of 2-CdA with or without rituximab in the treatment of splenic marginal zone lymphoma (SMZL).
    Cervetti G; Galimberti S; Sordi E; Buda G; Orciuolo E; Cecconi N; Petrini M
    Ann Oncol; 2010 Apr; 21(4):851-854. PubMed ID: 19825880
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Risk adapted approach: How to treat splenic marginal zone lymphoma in resource-poor settings? - The real-life experience of a Brazilian cancer treatment center.
    de Pádua Covas Lage LA; Dos Santos FFC; Levy D; Moreira FR; Couto SCF; Culler HF; de Oliveira Costa R; Rocha V; Pereira J
    BMC Cancer; 2020 Aug; 20(1):717. PubMed ID: 32746790
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment patterns and comparative effectiveness in elderly diffuse large B-cell lymphoma patients: a surveillance, epidemiology, and end results-medicare analysis.
    Hamlin PA; Satram-Hoang S; Reyes C; Hoang KQ; Guduru SR; Skettino S
    Oncologist; 2014 Dec; 19(12):1249-57. PubMed ID: 25342313
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Analysis of hepatitis B surface antibody titers in B cell lymphoma patients after rituximab therapy.
    Pei SN; Ma MC; Wang MC; Kuo CY; Rau KM; Su CY; Chen CH
    Ann Hematol; 2012 Jul; 91(7):1007-12. PubMed ID: 22273839
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term follow-up analysis of 100 patients with splenic marginal zone lymphoma treated with splenectomy as first-line treatment.
    Lenglet J; Traullé C; Mounier N; Benet C; Munoz-Bongrand N; Amorin S; Noguera ME; Traverse-Glehen A; Ffrench M; Baseggio L; Felman P; Callet-Bauchu E; Brice P; Berger F; Salles G; Brière J; Coiffier B; Thieblemont C
    Leuk Lymphoma; 2014 Aug; 55(8):1854-60. PubMed ID: 24206091
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Splenic marginal zone lymphoma associated with autoimmune hemolytic anemia treated with splenectomy and rituximab].
    Miztani M; Noda T; Umino A; Tanigawa M; Taniguchi M; Tamaki S; Tsuji K
    Rinsho Ketsueki; 2007 Nov; 48(11):1489-91. PubMed ID: 18080507
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rituximab plus bendamustine is active in pretreated patients with extragastric marginal zone B cell lymphoma of the mucosa-associated lymphoid tissue (MALT lymphoma).
    Kiesewetter B; Mayerhoefer ME; Lukas J; Zielinski CC; Müllauer L; Raderer M
    Ann Hematol; 2014 Feb; 93(2):249-53. PubMed ID: 23925930
    [TBL] [Abstract][Full Text] [Related]  

  • 38. First-line treatment with bendamustine and rituximab, in patients with intermediate-/high-risk splenic marginal zone lymphomas.
    Castelli R; Bergamaschini L; Deliliers GL
    Med Oncol; 2017 Dec; 35(2):15. PubMed ID: 29288421
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinicopathological features of splenic tumours of lymphoid tissue.
    Chen DB; Shen DH; Yang SM; Fang XZ
    Pathol Res Pract; 2018 Dec; 214(12):1952-1958. PubMed ID: 30087035
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Stage IV marginal zone B-cell lymphoma--prognostic factors and the role of rituximab: Consortium for Improving Survival of Lymphoma (CISL) study.
    Oh SY; Kim WS; Kim JS; Kim SJ; Lee S; Lee DH; Won JH; Hwang IG; Kim MK; Lee SI; Chae YS; Yang DH; Kang HJ; Choi CW; Park J; Kim HJ; Kwon JH; Lee HS; Lee GW; Eom HS; Kwak JY; Suh C; Kim HJ
    Cancer Sci; 2010 Nov; 101(11):2443-7. PubMed ID: 20831770
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.